Thus, given that we found that p62 or SOX9 is not required for the viability of IL-1-treated HR+ BCa and/or PCa cells, p62 and SOX9 likely function in these other IL-1-regulated pro-tumorigenic pathways. This evidence concerns the gene SQSTM1 and posterior cortical atrophy.